Akeso Biopharma (HKG: 9926), a biopharmaceutical company based in China, has announced the first patient dosing in a Phase III clinical study for its drug candidate, cadonilimab, in combination with lenvatinib and transcatheter arterial chemoembolization (TACE) for the treatment of unresectable, non-metastatic hepatocellular carcinoma (HCC).
The study’s data for this indication have demonstrated that the combination therapy exhibits a high tumor response rate in advanced uHCC, effectively controlling tumor progression and providing sustained survival benefits to patients.
Cadonilimab, an innovative bispecific antibody targeting programmed death-1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), received conditional approval in China in June 2022 for the treatment of patients with recurrent or metastatic cervical cancer who have previously failed platinum-based chemotherapy. It is also under regulatory scrutiny in a Phase III study as an adjuvant therapy for postoperative HCC.- Flcube.com
